Prigerson, Holly G. http://orcid.org/0000-0002-7075-4268
Viola, Martin
Brewin, Chris R.
Cox, Christopher
Ouyang, Daniel
Rogers, Madeline
Pan, Cynthia X.
Rabin, Shayna
Xu, Jiehui
Vaughan, Susan
Gordon-Elliot, Janna S.
Berlin, David
Lief, Lindsay
Lichtenthal, Wendy G.
Funding for this research was provided by:
National Cancer Institute (CA218313, CA197730)
American Cancer Society (PEP-17-053-01)
Article History
Received: 7 February 2019
Accepted: 10 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: The EMPOWER study has been IRB-approved at NewYork-Presbyterian Hospital/Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and NewYork-Presbyterian Queens. This is protocol #1610017622A011, approved on May 9, 2019.Written informed consent will be obtained from participants by trained research assistants and will allow for permission to collect data from both the surrogate decision-maker and the incapacitated patient. Recruitment for this study began on July 12, 2017. Recruitment is expected to be completed by approximately June 28, 2020.Study participants will be assured that all responses will be kept confidential. All of the data collected during the interview process will be de-identified. Authorized study staff are the only individuals who have access to the participant’s personal information. This information is stored in a password-protected computer file as well as in a locked file cabinet in a locked office. All necessary precautions will be taken to ensure that there is no breach of confidentiality. As mentioned previously, confidentiality will only be broken if information regarding homicidality or suicidality is obtained.
: Not applicable.
: The authors declare that they have no competing interests.